Large trial shows clear heart benefits
A new clinical trial shows that tirzepatide reduces the risk of heart attacks in adults with type 2 diabetes. The drug, sold under the brand name Mounjaro, is already used to treat diabetes and obesity.
The study followed more than 13,000 patients for several years. Those taking tirzepatide had fewer heart attacks, strokes, and deaths from heart disease than those given a placebo.
Researchers said the benefits appeared within months and grew over time. The effect was seen across all age groups and in patients with or without a history of heart disease.
How the drug works
Tirzepatide belongs to a class of drugs that mimic natural hormones in the body. It helps lower blood sugar, reduce appetite, and promote weight loss.
Weight loss likely explains part of the heart benefit, but researchers say the drug appears to act on the heart and blood vessels directly as well. Blood pressure and cholesterol levels also improved in the treatment group. The trial was funded by the drug's maker and run at more than 300 hospitals.
Side effects were mostly mild and included nausea and digestive discomfort. Fewer patients in the treatment group stopped the drug because of side effects than in some earlier studies.
What it means for patients
Doctors say the results are likely to change how the drug is prescribed. Patients with diabetes and heart risk factors may now be offered tirzepatide earlier in their treatment.
Experts also expect the findings to strengthen arguments for broader insurance coverage. The drug is expensive, and many insurers restrict access to it. Patients should talk to their doctors before making any changes to their treatment.
The full results will be presented at a medical meeting later this year and submitted for publication. Regulators may update the drug's label to include the heart benefits.